InterPAD - DETAILS

acarbose, Glucobay, CHEBI:2376, Bay g 5421, MFCD00869592, Acarbose hydrate, BAY-g 5421, (3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol, 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose, SMR000466376, SR-01000759407, Glucobay;, Prandase;, Precose;, Acarbose,(S), Acarbose; O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enyl]amino]-a-d-glucopyranosyl-(1?4)-O-a-d-glucopyranosyl-(1?4)-d-glucopyranose, Precose (TN), Acarbose for identification, Acarbose (JAN/USAN/INN), MLS000759506, MLS001424056, MLS006011898, SPECTRUM1505172, CHEMBL404271, SCHEMBL5316305, Acarbose for peak identification, CHEMBL3734896, BDBM23406, XUFXOAAUWZOOIT-UGEKTDRHSA-N, HMS2051F03, HMS2093I22, HMS2236P06, Pharmakon1600-01505172, C25H43NO18;, BBL030515, BDBM50180587, NSC758915, STK801930, AKOS005622515, CCG-100913, CCG-213345, MD-0230, NC00163, NCGC00160515-01, (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol, SBI-0206777.P001, C06802, D00216, AB00639959-06, AB00639959_08, Abamectin, Antibiotic for Culture Media Use Only, Q-200574, SR-01000759407-4, SR-01000759407-5, SR-01000759407-6, BRD-A16444946-001-07-1, 4",6"-Dideoxy-4"-([1S]-[1,4,6/5]-4,5,6-trihydroxy-3-hydroxymethyl-2-yclohexenylamino)-maltotriose, 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; Precose (TN);

No.	Title	Href
1	DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50(D1):D1200-D1207. doi:10.1093/nar/gkab880	`Click`

No.

Title

Href

DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50(D1):D1200-D1207. doi:10.1093/nar/gkab880

Click

Name	Glucobay
PubChem CID	41774
Molecular Weight	645.6g/mol
Synonyms	acarbose, Glucobay, CHEBI:2376, Bay g 5421, MFCD00869592, Acarbose hydrate, BAY-g 5421, (3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol, 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose, SMR000466376, SR-01000759407, Glucobay;, Prandase;, Precose;, Acarbose,(S), Acarbose; O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enyl]amino]-a-d-glucopyranosyl-(1?4)-O-a-d-glucopyranosyl-(1?4)-d-glucopyranose, Precose (TN), Acarbose for identification, Acarbose (JAN/USAN/INN), MLS000759506, MLS001424056, MLS006011898, SPECTRUM1505172, CHEMBL404271, SCHEMBL5316305, Acarbose for peak identification, CHEMBL3734896, BDBM23406, XUFXOAAUWZOOIT-UGEKTDRHSA-N, HMS2051F03, HMS2093I22, HMS2236P06, Pharmakon1600-01505172, C25H43NO18;, BBL030515, BDBM50180587, NSC758915, STK801930, AKOS005622515, CCG-100913, CCG-213345, MD-0230, NC00163, NCGC00160515-01, (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol, SBI-0206777.P001, C06802, D00216, AB00639959-06, AB00639959_08, Abamectin, Antibiotic for Culture Media Use Only, Q-200574, SR-01000759407-4, SR-01000759407-5, SR-01000759407-6, BRD-A16444946-001-07-1, 4",6"-Dideoxy-4"-([1S]-[1,4,6/5]-4,5,6-trihydroxy-3-hydroxymethyl-2-yclohexenylamino)-maltotriose, 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; Precose (TN);
Drug Type	Small molecule
Formula	C₂₅H₄₃NO₁₈
SMILES	CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO
InChI	1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1
InChIKey	XUFXOAAUWZOOIT-UGEKTDRHSA-N
CAS Number	56180-94-0
ChEMBL ID	CHEMBL404271
ChEBI ID	CHEBI:2376
TTD ID	D0AD5C
Drug Bank ID	DB00284
KEGG ID	C06802
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Glucobay
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.